ISPOR Europe 2024 Home
Toggle navigation
About
News Center
Award Winners
Program
Program
Student Program
Learning Formats
Plenary Sessions
Posters
Program Committee
Digital Conference Pass
Exhibits & Sponsorship
Sponsor List
Media Partners
Exhibitor Directory
Photo Gallery
ISPOR
Europe 2024
17 - 20 November
Home
Events
Past Conferences
ISPOR Europe 2024
Program
Plenary Sessions
Session
Cost-Effectiveness of Glofitamab vs Chemoimmunotherapy Regimens for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RRDLBCL) After at Least Two Lines of Systemic Therapy in the Czech Republic
Nov 18, 2024, 16:00 PM
«
2311
2312
2313
2314
2315
2316
2317
2318
2319
2320
(current)
»